|
Douglas Abel was appointed President and Chief Executive Officer in April 2005. He previously served in the same roles at Tarpan Therapeutics, a closely-held company acquired by Manhattan Pharmaceuticals. Before joining Tarpan, Mr. Abel served as Vice President of the Dermatology Business Unit at Biogen Idec where he worked from August 2000 to November 2004. While at Biogen, he led the creation of the U.S. dermatology commercial operation, building the team from two to more than 100 employees to support the launch of AMEVIVE�. Before that, Mr. Abel was at Allergan Pharmaceuticals from December 1987 to August of 2000, with his most recent position being Director of BOTOX� Marketing. Mr. Abel received his AB in chemistry from Lafayette College and an MBA from Temple University. | 